KATIE WOOD: Open Payments
NPI 1558614172 · MADISON, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$268 in 17 payments from 8 companies in 2025. Trend: 2023 $24 · 2024 $369 · 2025 $268
Food & beverage: $268
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 4 | $83 |
| Novo Nordisk Inc | 3 | $46 |
| AstraZeneca Pharmaceuticals LP | 3 | $42 |
| ABBVIE INC. | 2 | $33 |
| SANOFI-AVENTIS U.S. LLC | 1 | $20 |
| Astellas Pharma US Inc | 1 | $17 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $15 |
| Phathom Pharmaceuticals, Inc. | 2 | $12 |
Products named: REXULTI, TZIELD, QULIPTA, Veozah, Kerendia, Ozempic, AIRSUPRA, UBRELVY.
Industry payments across NE — which companies pay providers there.
